News | November 12, 2021
Solara Active Pharma Sciences PAT slides to Rs 29.71 cr in Q2FY22
Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.
Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.
J. B. Chemicals & Pharmaceuticals Limited (JBCPL), announced its financial results for the second quarter ended 30th September, 2021
The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
LSDCheck is CE-IVD approved LCMSMS-based testing kit for LSD in newborns
The consideration for the acquisition is US $ 2.25 million
Glycopyrrolate injection can also be used in adults as an adjunctive therapy for the treatment of gastrointestinal ulcer when a rapid effect is desired or when oral medication is not tolerated
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22
Subscribe To Our Newsletter & Stay Updated
